NextTrip (NTRP) 10-K 30 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 29, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38015
Entity Registrant Name	SIGMA ADDITIVE SOLUTIONS, INC.
Entity Central Index Key	0000788611
Entity Tax Identification Number	27-1865814
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3900 Paseo del Sol
Entity Address, City or Town	Santa Fe
Entity Address, State or Province	NM
Entity Address, Postal Zip Code	87507
City Area Code	(505)
Local Phone Number	438-2576
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SASI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 13,340,270
Entity Common Stock, Shares Outstanding		10,772,713
Documents Incorporated By Reference	None
ICFR Auditor Attestation Flag	false
Auditor Firm ID	457
Auditor Name	Haynie
Auditor Location	Salt Lake City, Utah

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 2,845,931	$ 11,447,047
Accounts Receivable, net	371,620	412,192
Inventory	950,943	710,080
Prepaid Assets	105,226	114,278
Total Current Assets	4,273,720	12,683,597
Other Assets:
Property and Equipment, net	304,903	232,282
Intangible Assets, net	1,125,285	925,111
Total Other Assets	1,430,188	1,157,393
TOTAL ASSETS	5,703,908	13,840,990
Current Liabilities:
Accounts Payable	277,492	206,442
Deferred Revenue	120,073	148,855
Accrued Expenses	231,633	625,942
Total Current Liabilities	629,198	981,239
TOTAL LIABILITIES	629,198	981,239
Commitments & Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 465 shares issued and outstanding	1	1
Common Stock, $0.001 par value; 24,000,000 shares authorized; 10,498,802 shares issued and outstanding	10,499	10,499
Additional Paid-In Capital	54,406,694	53,442,431
Accumulated Deficit	(49,342,484)	(40,593,180)
Total Stockholders’ Equity	5,074,710	12,859,751
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 5,703,908	$ 13,840,990

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	465	465
Preferred stock, shares outstanding	465	465
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	24,000,000	24,000,000
Common stock, shares issued	10,498,802	10,498,802
Common stock, shares outstanding	10,498,802	10,498,802

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
REVENUES	$ 630,428	$ 1,651,765
COST OF REVENUE	349,930	559,965
GROSS PROFIT	280,498	1,091,800
EXPENSES:
Salaries & Benefits	4,740,437	4,286,368
Stock-Based Compensation	793,251	1,066,455
Operations and R&D Costs	653,194	890,553
Investor, Public Relations and Marketing	422,645	503,823
Organizational Costs	311,606	726,147
Legal & Professional Service Fees	725,285	915,530
Office Expenses	914,802	734,386
Depreciation & Amortization	116,167	94,105
Other Operating Expenses	352,115	353,818
Total Operating Expenses	9,029,502	9,571,185
LOSS FROM OPERATIONS	(8,749,004)	(8,479,385)
OTHER INCOME (EXPENSE)
Interest Income	3,487	13,866
State Incentives	76,628
Exchange Rate Loss	(16,190)	(263)
Other Income		1,092,441
Interest Expense	(7,345)	(11,264)
Total Other Income (Expense)	56,580	1,094,780
LOSS BEFORE PROVISION FOR INCOME TAXES	(8,692,424)	(7,384,605)
Provision for Income Taxes
Net Loss	(8,692,424)	(7,384,605)
Preferred Dividends	56,880	103,567
Net Loss applicable to Common Stockholders	$ (8,749,304)	$ (7,488,172)
Net Loss per Common Share - Basic and Diluted	$ (0.83)	$ (0.76)
Weighted Average Number of Shares Outstanding - Basic and Diluted	10,498,802	9,828,541

Statement of Stockholders' Equi

Statement of Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1	$ 5,995	$ 38,262,744	$ (33,105,008)	$ 5,163,732
Beginning balance, shares at Dec. 31, 2020	715	5,995,320
Common Shares Sold in Public Offerings		$ 3,902	14,865,997		14,869,899
Common Shares Sold in Public Offerings, shares		3,901,783
Gain on Derivative Liability			(1,092,441)		(1,092,441)
Preferred Stock Dividends		$ 19	103,548	(103,567)
Preferred Stock Dividends, shares		19,000
Common Shares Issued for Conversion of Preferred Shares		$ 100	(100)
Common Shares Issued for Conversion of Preferred Shares, shares	(250)	100,000
Common Shares Issued for Exercise of Common Warrants		$ 476	1,135,534		1,136,010
Common Shares issued for Exercise of Common Warrants, shares		475,995
Securities Issued to Directors for Services			538,585		538,585
Securities Issued for Third Party Services		$ 2	163,081		163,083
Securities Issued for Third Party Services, shares		1,500
Securities Awarded to Employees		$ 5	1,066,450		1,066,455
Securities Awarded to Employees, shares		5,204
Offering Costs			(1,600,967)		(1,600,967)
Net Loss				(7,384,605)	(7,384,605)
Ending balance, value at Dec. 31, 2021	$ 1	$ 10,499	53,442,431	(40,593,180)	12,859,751
Ending balance, shares at Dec. 31, 2021	465	10,498,802
Preferred Stock Dividends			56,880	(56,880)
Securities Issued to Directors for Services			88,756		88,756
Securities Issued for Third Party Services			25,376		25,376
Securities Awarded to Employees			793,251		793,251
Net Loss				(8,692,424)	(8,692,424)
Ending balance, value at Dec. 31, 2022	$ 1	$ 10,499	$ 54,406,694	$ (49,342,484)	$ 5,074,710
Ending balance, shares at Dec. 31, 2022	465	10,498,802

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
OPERATING ACTIVITIES
Net Loss	$ (8,692,424)	$ (7,384,605)
Noncash Expenses:
Depreciation and Amortization	116,167	94,105
Gain on Derivative Liability		(1,092,441)
Stock Based Compensation - Employees	793,251	1,066,455
Stock Based Compensation - Third Party Services	25,376	163,083
Stock Based Compensation - Directors	88,756	538,585
Change in assets and liabilities:
Accounts Receivable	40,572	(80,630)
Inventory	(240,863)	(50,429)
Prepaid Assets	9,052	2,457
Accounts Payable	71,050	77,505
Deferred Revenue	(28,782)	70,898
Accrued Expenses	(394,309)	382,127
Long-Term portion of Stock Appreciation Rights		(48,341)
Long-Term portion of Deferred Payroll Taxes under the CARES Act		(37,728)
NET CASH USED IN OPERATING ACTIVITIES	(8,212,154)	(6,298,959)
INVESTING ACTIVITIES
Purchase of Property and Equipment	(164,622)	(182,522)
Purchase of Intangible Assets	(224,340)	(177,228)
NET CASH USED IN INVESTING ACTIVITIES	(388,962)	(359,750)
FINANCING ACTIVITIES
Gross Proceeds from Public and Private Issuances of Securities		14,869,899
Less Offering Costs		(1,600,967)
Proceeds from Exercise of Warrants		1,136,010
NET CASH PROVIDED BY FINANCING ACTIVITIES		14,404,942
NET CHANGE IN CASH FOR PERIOD	(8,601,116)	7,746,233
CASH AT BEGINNING OF PERIOD	11,447,047	3,700,814
CASH AT END OF PERIOD	2,845,931	11,447,047
Noncash investing and financing activities disclosure:
Issuance of Common Shares for Preferred Dividends		103,567
Other noncash operating activities disclosure:
Issuance of Securities for Services	114,132	701,668
Disclosure of cash paid for:
Interest	7,345	11,264
Income Taxes

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 – Summary of Significant Accounting Policies Nature of Business Basis of Presentation Going Concern The Company did not raise any capital in 2022. In 2021, the Company relied on both public and private offerings to finance its operations. In January 2021, the Company closed a public offering of our common stock in which it issued 1,711,783 3.00 4,532,444 2,190,000 4.445 8,736,488 454,404 1,136,010 The continuing operations of the Company are no longer solely dependent upon financing the cost of product development in the absence of revenues, but rather upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the product validation of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate the growth of revenues. The Company currently has sufficient cash and working capital to fund operations through May 2023 and will require additional funding in the public or private markets in the near-term to be able to continue operations. The Company currently has no understanding or agreement to obtain such funding, and there is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we will be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations. As a result, there is substantial doubt about our ability to continue as a going concern. Loss Per Share Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Year Ended December 31, 2022 2021 Warrants 3,823,279 3,987,931 Stock Options 1,799,053 1,395,882 Preferred Stock 148,918 148,918 Total Underlying Common Shares 5,771,250 5,532,731 Property and Equipment In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. Income Taxes The Company has no tax positions at December 31, 2022 and 2021 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2022 and 2021, the Company recognized no Accounts Receivable and Allowance for Doubtful Accounts no Long-Lived and Intangible Assets No 10,510 17 Cash Equivalents Fair Value of Financial Instruments The Company does not use derivative instruments for hedging of market risk or for trading or speculative purposes. On March 26, 2021, the Company closed an offering in which it issued warrants to purchase an aggregate of 2,190,000 May 24, 2021 12,000,000 24,000,000 two years Pursuant to ASC 815.40.25.10, such warrants were accounted for as a derivative liability because the Company did not have sufficient authorized and unissued shares of common stock available to settle the warrants at the issue date. On May 24, 2021, upon receiving stockholder approval to increase its authorized common shares, the Company reclassified the warrant liability to equity pursuant to ASC 815.40.35.8. For the twelve months ended December 31, 2021, the Company recorded a gain of $ 1,092,441 Concentration of Credit Risk Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 718. In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification. Amortization 17 Accounting Estimates Leases Revenue Recognition Revenue from Contracts with Customers In January 2022, the Company began offering a subscription option to its customers, pursuant to which it leases its PrintRite3D platform for terms between 12 and 36 months and provide technical support and maintenance for the term of the arrangement, as well as installation and training. The Company has determined these are leases because they relate to discrete pieces of equipment to which customers have the right to substantially all the economic benefit from and exclusive right to use during the term of the arrangement. These leases are classified as operating leases and the Company retains title to the underlying equipment. The leases may be renewed for successive one-year terms unless notice is given by either party of its intent not to renew at least 30 days before the end of the lease term. For leases with 36-month terms, the lessee may terminate the agreement after the first 18 months with 30-days written notice. Some, but not all, of the leases permit lessees to purchase the equipment at any time at an amount that approximates fair value and are not reasonably certain to be exercised at the inception of the lease. There are no anticipated variable lease payments at the inception of the lease. There are two non-lease components in the arrangement that consist of technical support and maintenance, and installation and training. The Company has elected the single component practical expedient to combine the technical support and maintenance with the lease as they have the same pattern of transfer. The installation and training component does not have the same pattern of transfer; therefore, this component is not eligible for the single component practical expedient. The consideration has been allocated on a relative fair value basis of the underlying lease and non-lease components. The Company has estimated the residual value of the leased equipment based on its useful life, and the ability to refurbish and sell the equipment, as well as the Company’s ability to componentize the hardware and utilize subassemblies in other products. Revenue from these operating leases for the twelve months ended December 31, 2022 was $ 31,177 Minimum Lease Payments Receivable Minimum lease payments receivable for each of the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 $ 45,348 2024 $ 8,503 2025 - 2026 and thereafter - Total $ 53,851 Equipment Underlying Operating Leases: Equipment under operating leases as of December 31, 2022 was comprised of the following: Schedule of Assets underlying Operating Leases December 31, PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (6,931 ) Net Book Value $ 70,277 The Company is depreciating the underlying equipment over its useful life of 7 Deferred Stock Offering Costs Inventory Research and Development 404,720 417,744

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	NOTE 2 - Inventory At December 31, 2022 and December 31, 2021, the Company’s inventory was comprised of: Schedule of Inventory December 31 2022 December 31, 2021 Raw Materials $ 294,194 $ 202,015 Work in Process 140,723 224,079 Finished Goods 516,026 283,986 Total Inventory $ 950,943 $ 710,080

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 – Property and Equipment The following is a summary of property and equipment, less accumulated depreciation, as of December 31, 2022 and 2021: Schedule of Property and Equipment 2022 2021 Year Ended December 31, 2022 2021 Property and Equipment $ 1,543,594 $ 1,378,972 Less: Accumulated Depreciation (1,238,691 ) (1,146,690 ) Net Property and Equipment $ 304,903 $ 232,282 Depreciation expense on property and equipment was $ 92,001 88,866

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 4 – Intangible Assets The Company’s intangible assets consist of patents and patent pending applications. The Company capitalizes costs incurred in connection with acquiring its patents. These costs include registration, documentation, and legal fees associated with the application. Costs incurred with patents that have been granted are expensed as incurred. Provisional patent applications are not amortized until a patent has been granted. Once a patent is granted, the Company will amortize the related costs over the estimated useful life of the patent. If a patent application is denied, then the costs will be expensed at that time. During 2022, $ 206,110 The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2022 and 2021, respectively: Summary of Definite-life Intangible Assets and Accumulated Amortization 2022 2021 Year Ended December 31, 2022 2021 Provisional Patent Applications $ 675,251 $ 675,291 Patents 524,750 300,370 Less: Accumulated Amortization (74,716 ) (50,550 ) Net Intangible Assets $ 1,125,285 $ 925,111 Amortization expense on intangible assets was $ 24,166 5,239 The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: Schedule of Aggregate Amortization Expense 2023 $ 29,570 2024 29,570 2025 29,570 2026 29,570 Thereafter 331,752 Intangible asset and amortization expense $ 450,032

Deferral of Social Security Tax

Deferral of Social Security Tax Payments	12 Months Ended
	Dec. 31, 2022
Deferral Of Social Security Tax Payments
Deferral of Social Security Tax Payments	NOTE 5 – Deferral of Social Security Tax Payments Pursuant to sections 2302(a)(1) and (a)(2) of the CARES Act, the Company elected to defer payments of its share of Social Security tax due during the “payroll tax deferral period”. The payroll tax deferral period began on March 27, 2020 and ended on December 31, 2020. At December 31, 2022 the total remaining amount of the deferral of $ 37,728

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	NOTE 6 – Stockholders’ Equity Common Stock During 2022, the Company did not issue any common stock. In January 2021, the Company closed a public offering of its securities in which it issued 1,711,783 3.00 4,532,445 136,943 five years 3.75 In February 2021, the Company issued 263,200 In March 2021, the Company issued 119,000 250 19,000 191,204 21,591 In March 2021, the Company closed a public offering of its securities in which it issued 2,190,000 4.445 8,736,488 2,190,000 4.32 May 24, 2021 two years 175,200 8 125 5.55625 8.0 In March 2021, Company issued 1,500 4.99 In September 2021, the Company granted 5,204 Deferred Compensation During 2022, the Company did not issue any shares of common stock to employees. In 2021, the Company issued to various employees shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”). Such shares were valued at the fair value at the date of issue. The fair value was expensed as compensation over the vesting period and recorded as a reduction of stockholders’ equity. The shares were fully vested as of December 31, 2021, and $ 19,255 Preferred Stock The Company is authorized to issue 10,000,000 0.001 465 In January 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Institutional Private Placement”). Pursuant to the SPA, the Company issued and sold 1,640 1,000 9 2.50 In addition, a holder may at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price, which equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion. Upon the occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment defaults, breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set forth therein, the Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium to the underlying value of the Series D Preferred Shares being redeemed At December 31, 2022, there were 132 87,267 Concurrent with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain of its directors and the Company’s formerly largest shareholder (the “Other Private Placement”). Pursuant to the SPA, the Company issued and sold 333 9 48,544 At December 31, 2022, all of the issued Series E Convertible Preferred Stock were outstanding, which if converted as of December 31, 2022, including the make-whole dividends, would have resulted in the issuance of 61,651 Stock Options On August 9, 2022, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 500,000 2,265,000 436,506 During 2022, the Company granted a total of 487,473 three years 406,879 907,373 1,799,053 1,749,053 1,294,021 No During 2021, the Company granted a total of 698,831 three years 598,789 1,741,366 1,395,882 1,345,882 941,934 5,204 The Company generally grants stock options to employees, consultants and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over three years of service and expire five years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award. Total employee share-based compensation expense for the year ended December 31, 2022, was $ 793,251 1,066,455 1,047,200 To estimate the value of an award, the Company uses the Black-Scholes option-pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. The forfeiture rate also impacts the amount of aggregate compensation. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life, volatility and forfeiture rate are derived primarily from the Company’s historical data, the risk-free rate is based on the yield available on U.S. Treasury constant maturity rates with similar terms to the expected term of the stock option awards. The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2022 and 2021: Schedule of Share Based Payment Award Stock Option Valuations Assumptions Assumptions: 2022 2021 Dividend yield 0.00 % 0.00 % Risk-free interest rate 0.95 3.88 % 0.19 0.67 % Expected volatility 106.0 110.0 % 117.0 124.0 % Expected life (in years) 5 5 Option activity for the year ended December 31, 2022 and 2021 was as follows: Schedule of Share Based Compensation Stock Option Activity Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2020 713,010 5.15 4.40 477,802 Granted 698,831 3.29 4.39 46,800 Exercised (5,204 ) 2.50 - - Forfeited or cancelled (10,755 ) 3.49 - - Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Options expected to vest in the future as of December 31, 2021 453,948 3.64 4.07 - Options exercisable at December 31, 2021 941,934 4.53 3.81 - Options vested, exercisable, and options expected to vest at December 31, 2021 1,395,882 4.24 3.89 - Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Granted 487,473 2.50 4.43 - Exercised - - - - Forfeited or cancelled (84,302 ) 4.39 - - Options outstanding at December 31, 2022 1,799,053 3.76 3.30 - Options expected to vest in the future as of December 31, 2022 505,032 2.83 3.98 - Options exercisable at December 31, 2022 1,294,021 4.13 3.03 - Options vested, exercisable, and options expected to vest at December 31, 2022 1,799,053 3.76 3.30 - The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price below the $ 0.40 0.40 At December 31, 2022, there was $ 741,728 1.81 Stock Appreciation Rights On June 23, 2020, the Board of Directors (the “Board”) of the Company adopted the Sigma Labs, Inc. 2020 Stock Appreciation Rights Plan (the “Plan”). The purposes of the Plan are to: (i) enable the Company to attract and retain the types of employees, consultants, and directors (collectively, “Service Providers”) who will contribute to the Company’s long-range success; (ii) provide incentives that align the interests of Service Providers with those of the shareholders of the Company; and (iii) promote the success of the Company’s business. The Plan provides for incentive awards that are only made in the form of stock appreciation rights payable in cash (“SARs”). No shares of common stock were reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the Plan. SARs may be granted to any Service Provider. A SAR is the right to receive an amount equal to the Spread with respect to a share of the Company’s common stock (“Share”) upon the exercise of the SAR. The “Spread” is the difference between the exercise price per share specified in a SAR agreement on the date of grant and the fair market value per share on the date of exercise of the SAR. The exercise price per share will not be less than 100% of the fair market value of a Share on the date of grant of the SAR. The administrator of the Plan will have the authority to, among other things, prescribe the terms and conditions of each SAR, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the SAR Agreement relating to such grant. On January 3, 2022, the Company granted, pursuant to the Plan, 12,033 1.87 On February 16, 2022, the company issued, pursuant to the Plan, 30,000 2.50 On July 1, 2022, the Company granted, pursuant to the Plan, (i) 194,940 25,117 16,944 69,470 2.50 Also on July 1, 2022, the Company granted, pursuant to the Plan, and employee retention agreements (i) 181,947 87,335 97,038 97,038 1.30 On March 31, 2022, we granted 3,000 On August 11, 2021, the Company granted, pursuant to the Plan, (i) 77,748 30,313 76,304 48,580 3.42 In the event of a Change in Control (as defined in the Plan), all SARs will become immediately vested and exercisable as long as the holder is in the Company’s employ immediately prior to the Change in Control, and will otherwise be on such terms set forth in our standard form Stock Appreciation Rights Agreement. On July 29, 2021, we granted 10,000 13,500 The Company recognizes compensation expense and a corresponding liability for the fair value of the SARs over the requisite service period for each SAR award. The SAR’s are revalued at each reporting date in accordance with ASC 718 “Compensation-Stock Compensation”, and any changes in fair value are reflected in income as of the applicable reporting date. The fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the twelve months ended December 31, 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions Assumptions: 2022 2021 Dividend yield 0.00 % 0.00 % Risk-free interest rate 0.82 2.79 % 0.39 0.40 % Expected volatility 108.0 119.0 % 123.0 % Expected life (in years) 5 5 SARs activity for the years ended December 31, 2022 and 2021 was as follows: Schedule of Stock Option Activity Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic SARs ($) Life (Yrs.) Value ($) SARs outstanding at December 31, 2020 127,679 2.61 4.52 97,919 Granted 242,945 3.43 4.61 - Exercised - - - - Forfeited or cancelled - - - - SARs outstanding December 31, 2021 370,624 3.15 4.24 - SARs expected to vest in the future as of December 31, 2021 309,065 3.23 4.33 - SARs exercisable at December 31, 2021 61,559 2.78 3.75 - SARs vested, exercisable, and options expected to vest at December 31, 2021 370,624 3.15 4.24 - SARs outstanding at December 31, 2021 370,624 3.15 4.24 - Granted 814,862 1.81 4.48 - Exercised - - - - Forfeited or cancelled (27,699 ) 2.91 - - SARs outstanding December 31, 2022 1,157,787 2.21 4.11 - SARs expected to vest in the future as of December 31, 2022 876,319 2.03 4.25 - SARs exercisable at December 31, 2022 281,468 2.76 3.68 - SARs vested, exercisable, and options expected to vest at December 31, 2022 1,157,787 2.21 4.11 - The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price below the $ 0.40 0.40 At December 31, 2022, there was $ 982,519 2.14 Warrants At December 31, 2022, the Company had outstanding warrants to purchase a total of 3,823,279 2.50 17.50 expire between May 24, 2023 and January 8, 2026 Warrant activity for the years ended December 31, 2022 and 2021 was as follows: Schedule of Warranty Activity Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2020 1,881,429 7.57 4.16 Granted 2,602,143 4.36 1.63 Exercised (495,641 ) - - Forfeited or cancelled - - - Warrants outstanding at December 31, 2021 3,987,931 6.10 2.10 Granted - - - Exercised - - - Forfeited or cancelled (164,652 ) - - Warrants outstanding at December 31, 2022 3,823,279 4.66 1.19

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7 – Income Taxes The Company accounts for income taxes in accordance with ASC Topic No. 740. This standard requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. Income tax returns open for examination by the Internal Revenue Service consist of tax years ended December 31, 2019 through 2021. The Company had available at December 31, 2022 unused operating loss carryforwards of approximately $ 41,128,000 which may be applied against future taxable income 9,820,000 31,308,000 8,575,900 6,771,000 Deferred tax assets are comprised of the following: Schedule of Deferred Tax Assets 2022 2021 Deferred tax assets: NOL carryover $ 8,636,900 $ 6,729,300 Depreciation (61,000 ) 41,700 Valuation allowance (8,575,900 ) (6,771,000 ) Net deferred tax asset $ - $ - The reconciliation of the provision for income taxes computed at the U.S. federal statutory tax rate ( 21 Schedule of Reconciliation of the Provision for Income Taxes 2022 2021 Book Loss $ (1,837,400 ) $ (1,572,500 ) Depreciation (20,700 ) (25,700 ) Meals & Entertainment - 500 Stock Compensation (48,548 ) 340,521 Change in valuation allowance 1,906,648 1,257,179 Provision for Income Taxes $ - $ -

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Loss Per Share	NOTE 8 – Loss Per Share The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2022 and 2021: Schedule of Earnings Per Share, Basic and Diluted 2022 2021 Year Ended December 31 2022 2021 Loss from continuing Operations available to common stockholders (numerator) $ (8,749,304 ) $ (7,488,172 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 10,498,802 9,828,541 Dilutive loss per share was not presented as the Company’s outstanding common and preferred warrants, stock options and preferred stock common equivalent shares for the periods presented would have had an anti-dilutive effect. At December 31, 2022, the Company had outstanding warrants to purchase 3,823,279 shares of common stock, and stock options exercisable for 1,799,053 shares of common stock, 132 shares of Series D Preferred Stock, convertible into 87,267 shares of common stock, and 333 shares of Series E Preferred Stock, which could be converted into 61,651 shares of common stock, resulting in a potential total additional 5,771,250 shares of common stock outstanding in the future. At December 31, 2021, the Company had outstanding common warrants which could be converted to 3,987,931 shares of common stock, and stock options exercisable for 1,395,882 shares of common stock, 132 shares of Series D Preferred Stock, convertible into 87,267 shares of common stock, and 333 shares of Series E Preferred Stock, convertible into 61,651 shares of common stock, resulting in a potential total additional 5,532,731 shares of common stock outstanding in the future.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 – Commitments and Contingencies Operating Leases 108,099 101,004 7,233

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations	NOTE 10 – Concentrations Revenues 10 Schedule of Concentration of Risks Customer 2022 2021 A 12.85 % - B 12.2 % - C - 27.81 % D - 17.23 % Accounts Receivable 10 Customer 2022 2021 A 31.11 % 51.25 % B 24.49 % C 22.58 % - D - 46.34 %

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Defined Contribution Plan	NOTE 11 - Defined Contribution Plan The Company has adopted a qualified 401(K) plan (“the Plan”), in which all employees over the age of 21 may participate. The Company makes a Safe Harbor contribution match of 100% of each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed 99,341 86,554

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 12 – Related Party Transactions As of December 31, 2022, there are no related party transactions.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 – Subsequent Events On January 26, 2023, the Company agreed to issue to a holder of 132 shares of the Company’s outstanding Series D Preferred Stock (the “Preferred Shares”) a five-year warrant to purchase up to 225,000 shares of common stock of the Company at an initial exercise price of $ 0.58 per share, the closing price of the common stock as reported on the Nasdaq Capital Market on such date, which exercise price is subject to adjustment in the event of a stock split, reverse stock split and similar events. The warrant was issued in consideration of the holder’s agreement to convert, in full, the Series D Shares in accordance with their terms into 270,828 shares of common stock, which equates to a conversion price of $ 0.58 per share. In addition, the Company’s outstanding January 2020 warrants to purchase up to 516,400 shares of common stock and April 2020 warrants to purchase up to 383,306 shares of common stock, respectively, at an exercise price of $ 2.50 per share contain full-ratchet anti-dilution provisions that are triggered by the sale or issuance of common stock or common stock derivatives at an effective price per share below the exercise price of the warrants. As a result, the exercise price of each of the warrants was reduced to $ 0.58 per share and the number of shares purchasable upon exercise of the April 2020 warrants was increased to 1,648,302 . On January 18, 2023, pursuant to a conversion notice, we issued 3,083 16.67 10.30

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation	Basis of Presentation
Going Concern	Going Concern The Company did not raise any capital in 2022. In 2021, the Company relied on both public and private offerings to finance its operations. In January 2021, the Company closed a public offering of our common stock in which it issued 1,711,783 3.00 4,532,444 2,190,000 4.445 8,736,488 454,404 1,136,010 The continuing operations of the Company are no longer solely dependent upon financing the cost of product development in the absence of revenues, but rather upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the product validation of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate the growth of revenues. The Company currently has sufficient cash and working capital to fund operations through May 2023 and will require additional funding in the public or private markets in the near-term to be able to continue operations. The Company currently has no understanding or agreement to obtain such funding, and there is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we will be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations. As a result, there is substantial doubt about our ability to continue as a going concern.
Loss Per Share	Loss Per Share Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Year Ended December 31, 2022 2021 Warrants 3,823,279 3,987,931 Stock Options 1,799,053 1,395,882 Preferred Stock 148,918 148,918 Total Underlying Common Shares 5,771,250 5,532,731
Property and Equipment	Property and Equipment In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis.
Income Taxes	Income Taxes The Company has no tax positions at December 31, 2022 and 2021 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2022 and 2021, the Company recognized no
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts no
Long-Lived and Intangible Assets	Long-Lived and Intangible Assets No 10,510 17
Cash Equivalents	Cash Equivalents
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company does not use derivative instruments for hedging of market risk or for trading or speculative purposes. On March 26, 2021, the Company closed an offering in which it issued warrants to purchase an aggregate of 2,190,000 May 24, 2021 12,000,000 24,000,000 two years Pursuant to ASC 815.40.25.10, such warrants were accounted for as a derivative liability because the Company did not have sufficient authorized and unissued shares of common stock available to settle the warrants at the issue date. On May 24, 2021, upon receiving stockholder approval to increase its authorized common shares, the Company reclassified the warrant liability to equity pursuant to ASC 815.40.35.8. For the twelve months ended December 31, 2021, the Company recorded a gain of $ 1,092,441
Concentration of Credit Risk	Concentration of Credit Risk
Stock Based Compensation	Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 718. In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
Amortization	Amortization 17
Accounting Estimates	Accounting Estimates
Leases	Leases
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers In January 2022, the Company began offering a subscription option to its customers, pursuant to which it leases its PrintRite3D platform for terms between 12 and 36 months and provide technical support and maintenance for the term of the arrangement, as well as installation and training. The Company has determined these are leases because they relate to discrete pieces of equipment to which customers have the right to substantially all the economic benefit from and exclusive right to use during the term of the arrangement. These leases are classified as operating leases and the Company retains title to the underlying equipment. The leases may be renewed for successive one-year terms unless notice is given by either party of its intent not to renew at least 30 days before the end of the lease term. For leases with 36-month terms, the lessee may terminate the agreement after the first 18 months with 30-days written notice. Some, but not all, of the leases permit lessees to purchase the equipment at any time at an amount that approximates fair value and are not reasonably certain to be exercised at the inception of the lease. There are no anticipated variable lease payments at the inception of the lease. There are two non-lease components in the arrangement that consist of technical support and maintenance, and installation and training. The Company has elected the single component practical expedient to combine the technical support and maintenance with the lease as they have the same pattern of transfer. The installation and training component does not have the same pattern of transfer; therefore, this component is not eligible for the single component practical expedient. The consideration has been allocated on a relative fair value basis of the underlying lease and non-lease components. The Company has estimated the residual value of the leased equipment based on its useful life, and the ability to refurbish and sell the equipment, as well as the Company’s ability to componentize the hardware and utilize subassemblies in other products. Revenue from these operating leases for the twelve months ended December 31, 2022 was $ 31,177 Minimum Lease Payments Receivable Minimum lease payments receivable for each of the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 $ 45,348 2024 $ 8,503 2025 - 2026 and thereafter - Total $ 53,851 Equipment Underlying Operating Leases: Equipment under operating leases as of December 31, 2022 was comprised of the following: Schedule of Assets underlying Operating Leases December 31, PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (6,931 ) Net Book Value $ 70,277 The Company is depreciating the underlying equipment over its useful life of 7
Deferred Stock Offering Costs	Deferred Stock Offering Costs
Inventory	Inventory
Research and Development	Research and Development 404,720 417,744

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Year Ended December 31, 2022 2021 Warrants 3,823,279 3,987,931 Stock Options 1,799,053 1,395,882 Preferred Stock 148,918 148,918 Total Underlying Common Shares 5,771,250 5,532,731
Schedule of Minimum Lease Payments Receivable	Minimum lease payments receivable for each of the succeeding years ending December 31 are as follows: Schedule of Minimum Lease Payments Receivable Year ending December 31, Amount 2023 $ 45,348 2024 $ 8,503 2025 - 2026 and thereafter - Total $ 53,851
Schedule of Assets underlying Operating Leases	Equipment under operating leases as of December 31, 2022 was comprised of the following: Schedule of Assets underlying Operating Leases December 31, PrintRite 3D Hardware $ 77,208 Accumulated Depreciation (6,931 ) Net Book Value $ 70,277

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	At December 31, 2022 and December 31, 2021, the Company’s inventory was comprised of: Schedule of Inventory December 31 2022 December 31, 2021 Raw Materials $ 294,194 $ 202,015 Work in Process 140,723 224,079 Finished Goods 516,026 283,986 Total Inventory $ 950,943 $ 710,080

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following is a summary of property and equipment, less accumulated depreciation, as of December 31, 2022 and 2021: Schedule of Property and Equipment 2022 2021 Year Ended December 31, 2022 2021 Property and Equipment $ 1,543,594 $ 1,378,972 Less: Accumulated Depreciation (1,238,691 ) (1,146,690 ) Net Property and Equipment $ 304,903 $ 232,282

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Definite-life Intangible Assets and Accumulated Amortization	The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2022 and 2021, respectively: Summary of Definite-life Intangible Assets and Accumulated Amortization 2022 2021 Year Ended December 31, 2022 2021 Provisional Patent Applications $ 675,251 $ 675,291 Patents 524,750 300,370 Less: Accumulated Amortization (74,716 ) (50,550 ) Net Intangible Assets $ 1,125,285 $ 925,111
Schedule of Aggregate Amortization Expense	The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: Schedule of Aggregate Amortization Expense 2023 $ 29,570 2024 29,570 2025 29,570 2026 29,570 Thereafter 331,752 Intangible asset and amortization expense $ 450,032

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Share Based Payments Award Stock Options Valuation Assumptions	Schedule of Share Based Payment Award Stock Option Valuations Assumptions Assumptions: 2022 2021 Dividend yield 0.00 % 0.00 % Risk-free interest rate 0.95 3.88 % 0.19 0.67 % Expected volatility 106.0 110.0 % 117.0 124.0 % Expected life (in years) 5 5
Schedule of Stock Option Activity	Option activity for the year ended December 31, 2022 and 2021 was as follows: Schedule of Share Based Compensation Stock Option Activity Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2020 713,010 5.15 4.40 477,802 Granted 698,831 3.29 4.39 46,800 Exercised (5,204 ) 2.50 - - Forfeited or cancelled (10,755 ) 3.49 - - Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Options expected to vest in the future as of December 31, 2021 453,948 3.64 4.07 - Options exercisable at December 31, 2021 941,934 4.53 3.81 - Options vested, exercisable, and options expected to vest at December 31, 2021 1,395,882 4.24 3.89 - Options outstanding at December 31, 2021 1,395,882 4.24 3.89 - Granted 487,473 2.50 4.43 - Exercised - - - - Forfeited or cancelled (84,302 ) 4.39 - - Options outstanding at December 31, 2022 1,799,053 3.76 3.30 - Options expected to vest in the future as of December 31, 2022 505,032 2.83 3.98 - Options exercisable at December 31, 2022 1,294,021 4.13 3.03 - Options vested, exercisable, and options expected to vest at December 31, 2022 1,799,053 3.76 3.30 -
Schedule of Warranty Activity	Warrant activity for the years ended December 31, 2022 and 2021 was as follows: Schedule of Warranty Activity Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2020 1,881,429 7.57 4.16 Granted 2,602,143 4.36 1.63 Exercised (495,641 ) - - Forfeited or cancelled - - - Warrants outstanding at December 31, 2021 3,987,931 6.10 2.10 Granted - - - Exercised - - - Forfeited or cancelled (164,652 ) - - Warrants outstanding at December 31, 2022 3,823,279 4.66 1.19
Stock Appreciation Rights [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Share Based Payments Award Stock Options Valuation Assumptions	The fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the twelve months ended December 31, 2022: Schedule of Share Based Payments Award Stock Options Valuation Assumptions Assumptions: 2022 2021 Dividend yield 0.00 % 0.00 % Risk-free interest rate 0.82 2.79 % 0.39 0.40 % Expected volatility 108.0 119.0 % 123.0 % Expected life (in years) 5 5
Schedule of Stock Option Activity	SARs activity for the years ended December 31, 2022 and 2021 was as follows: Schedule of Stock Option Activity Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic SARs ($) Life (Yrs.) Value ($) SARs outstanding at December 31, 2020 127,679 2.61 4.52 97,919 Granted 242,945 3.43 4.61 - Exercised - - - - Forfeited or cancelled - - - - SARs outstanding December 31, 2021 370,624 3.15 4.24 - SARs expected to vest in the future as of December 31, 2021 309,065 3.23 4.33 - SARs exercisable at December 31, 2021 61,559 2.78 3.75 - SARs vested, exercisable, and options expected to vest at December 31, 2021 370,624 3.15 4.24 - SARs outstanding at December 31, 2021 370,624 3.15 4.24 - Granted 814,862 1.81 4.48 - Exercised - - - - Forfeited or cancelled (27,699 ) 2.91 - - SARs outstanding December 31, 2022 1,157,787 2.21 4.11 - SARs expected to vest in the future as of December 31, 2022 876,319 2.03 4.25 - SARs exercisable at December 31, 2022 281,468 2.76 3.68 - SARs vested, exercisable, and options expected to vest at December 31, 2022 1,157,787 2.21 4.11 -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets are comprised of the following: Schedule of Deferred Tax Assets 2022 2021 Deferred tax assets: NOL carryover $ 8,636,900 $ 6,729,300 Depreciation (61,000 ) 41,700 Valuation allowance (8,575,900 ) (6,771,000 ) Net deferred tax asset $ - $ -
Schedule of Reconciliation of the Provision for Income Taxes	Schedule of Reconciliation of the Provision for Income Taxes 2022 2021 Book Loss $ (1,837,400 ) $ (1,572,500 ) Depreciation (20,700 ) (25,700 ) Meals & Entertainment - 500 Stock Compensation (48,548 ) 340,521 Change in valuation allowance 1,906,648 1,257,179 Provision for Income Taxes $ - $ -

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2022 and 2021: Schedule of Earnings Per Share, Basic and Diluted 2022 2021 Year Ended December 31 2022 2021 Loss from continuing Operations available to common stockholders (numerator) $ (8,749,304 ) $ (7,488,172 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 10,498,802 9,828,541

Concentrations (Tables)

Concentrations (Tables)	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Schedule of Concentration of Risks	Schedule of Concentration of Risks Customer 2022 2021 A 12.85 % - B 12.2 % - C - 27.81 % D - 17.23 % Accounts Receivable 10 Customer 2022 2021 A 31.11 % 51.25 % B 24.49 % C 22.58 % - D - 46.34 %

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	5,771,250	5,532,731
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	3,823,279	3,987,931
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	1,799,053	1,395,882
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Underlying Common Shares	148,918	148,918

Schedule of Minimum Lease Payme

Schedule of Minimum Lease Payments Receivable (Details)	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
2023	$ 45,348
2024	8,503
2025
2026 and thereafter
Total	$ 53,851

Schedule of Assets underlying O

Schedule of Assets underlying Operating Leases (Details)	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
PrintRite 3D Hardware	$ 77,208
Accumulated Depreciation	(6,931)
Net Book Value	$ 70,277

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended	12 Months Ended
	Mar. 26, 2021	Jan. 31, 2021	Mar. 31, 2021	Jan. 31, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 25, 2021
Subsidiary, Sale of Stock [Line Items]
Public offering of common stock		1,711,783
Income taxes, interest and penalties						$ 0	$ 0
Allowance for doubtful accounts receivable						0	0
Patents written off						$ 0	$ 10,510
Finite-lived intangible asset, useful life						17 years
Aggregate warrant purchase of shares	2,190,000
Warrant exercisable date	May 24, 2021
Common shares authorized	24,000,000					24,000,000	24,000,000	12,000,000
Warrant expiration term	2 years	5 years		5 years
Derivative liability							$ 1,092,441
Lease income from operating leases						$ 31,177
Underlying equipment useful life						7 years
Research and development costs						$ 404,720	$ 417,744
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Public offering of common stock			2,190,000	1,711,783	454,404
Share price		$ 3	$ 4.445	$ 3	$ 4.445
Proceeds from Issuance of Common Stock			$ 8,736,488	$ 4,532,444	$ 1,136,010

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw Materials	$ 294,194	$ 202,015
Work in Process	140,723	224,079
Finished Goods	516,026	283,986
Total Inventory	$ 950,943	$ 710,080

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	$ 1,543,594	$ 1,378,972
Less: Accumulated Depreciation	(1,238,691)	(1,146,690)
Net Property and Equipment	$ 304,903	$ 232,282

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 92,001	$ 88,866

Summary of Definite-life Intang

Summary of Definite-life Intangible Assets and Accumulated Amortization (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Less: Accumulated Amortization	$ (74,716)	$ (50,550)
Net Intangible Assets	1,125,285	925,111
Provisional Patent Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Patents	675,251	675,291
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Patents	$ 524,750	$ 300,370

Schedule of Aggregate Amortizat

Schedule of Aggregate Amortization Expense (Details)	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 29,570
2024	29,570
2025	29,570
2026	29,570
Thereafter	331,752
Intangible asset and amortization expense	$ 450,032

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense on intangible assets	$ 24,166	$ 5,239
Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Costs relate to patents issued	$ 206,110

Deferral of Social Security T_2

Deferral of Social Security Tax Payments (Details Narrative)	Dec. 31, 2022 USD ($)
Deferral Of Social Security Tax Payments
Deferred Liabilities	$ 37,728

Schedule of Share Based Payment

Schedule of Share Based Payment Award Stock Option Valuations Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Dividend yield	0%	0%
Risk-free interest rate, minimum	0.95%	0.19%
Risk-free interest rate, maximum	3.88%	0.67%
Expected volatility, minimum	106%	117%
Expected volatility, maximum	110%	124%
Expected life	5 years	5 years

Schedule of Share Based Compens

Schedule of Share Based Compensation Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options, Outstanding, Beginning Balance	1,395,882	713,010
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 4.24	$ 5.15
Weighted Average Remaining Contractual Life Years, Outstanding Ending Balance	3 years 3 months 18 days	3 years 10 months 20 days	4 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance		$ 477,802
Number of Options, Granted	487,473	698,831
Weighted Average Exercise Price, Granted	$ 2.50	$ 3.29
Weighted Average Remaining Contractual Life Years, Granted	4 years 5 months 4 days	4 years 4 months 20 days
Aggregate Intrinsic Value, Granted		$ 46,800
Number of Options, Exercised	0	(5,204)
Weighted Average Exercise Price, Exercised		$ 2.50
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	(84,302)	(10,755)
Weighted Average Exercise Price, Forfeited or cancelled	$ 4.39	$ 3.49
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	1,799,053	1,395,882	713,010
Weighted Average Exercise Price, Outstanding Ending Balance	$ 3.76	$ 4.24	$ 5.15
Aggregate Intrinsic Value, Outstanding, Ending Balance			$ 477,802
Number of Options, Expected to Vest in the Future Ending Balance	505,032	453,948
Weighted Average Exercise Price, Expected to Vest	$ 2.83	$ 3.64
Weighted Average Remaining Contractual Life Years, Expected to Vest	3 years 11 months 23 days	4 years 25 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	1,294,021	941,934
Weighted Average Exercise Price, Exercisable	$ 4.13	$ 4.53
Weighted Average Remaining Contractual Life Years, Exercisable	3 years 10 days	3 years 9 months 21 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	1,799,053	1,395,882
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 3.76	$ 4.24
Weighted Average Remaining Contractual Life (Yrs.), Vested, Exercisable and Options Expected to Vest	3 years 3 months 18 days	3 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 3.76	$ 4.24

Schedule of Share Based Payme_2

Schedule of Share Based Payments Award Stock Options Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield	0%	0%
Risk-free interest rate, minimum	0.95%	0.19%
Risk-free interest rate, maximum	3.88%	0.67%
Expected volatility, minimum	106%	117%
Expected volatility, maximum	110%	124%
Expected life	5 years	5 years
2020 Stock Appreciation Rights Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield	0%	0%
Risk-free interest rate, minimum	0.82%	0.39%
Risk-free interest rate, maximum	2.79%	0.40%
Expected volatility, minimum	108%
Expected volatility, maximum	119%
Expected volatility		123%
Expected life	5 years		5 years

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning Balance	1,395,882	713,010
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 4.24	$ 5.15
Weighted Average Remaining Contractual Life, Outstanding Balance	3 years 3 months 18 days	3 years 10 months 20 days	4 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance		$ 477,802
Number of Options, Granted	487,473	698,831
Weighted Average Exercise Price, Granted	$ 2.50	$ 3.29
Aggregate Intrinsic Value, Granted		$ 46,800
Number of Options, Exercised	0	(5,204)
Weighted Average Exercise Price, Exercised		$ 2.50
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	84,302	10,755
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	1,799,053	1,395,882	713,010
Weighted Average Exercise Price, Outstanding Ending Balance	$ 3.76	$ 4.24	$ 5.15
Aggregate Intrinsic Value, Outstanding, Ending Balance			$ 477,802
Number of Options, Expected to Vest in the Future Ending Balance	505,032	453,948
Weighted Average Exercise Price, Expected to Vest	$ 2.83	$ 3.64
Weighted Average Remaining Contractual Life, Expected to Vest	3 years 11 months 23 days	4 years 25 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	1,294,021	941,934
Weighted Average Exercise Price, Exercisable	$ 4.13	$ 4.53
Weighted Average Remaining Contractual Life, Exercisable	3 years 10 days	3 years 9 months 21 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	1,799,053	1,395,882
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 3.76	$ 4.24
Weighted Average Remaining Contractual Life, Vested, Exercisable and Options Expected to Vest	3 years 3 months 18 days	3 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest
Number of Options, Forfeited or cancelled	(84,302)	(10,755)
Stock Appreciation Rights [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning Balance	370,624	127,679
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 3.15	$ 2.61
Weighted Average Remaining Contractual Life, Outstanding Balance	4 years 1 month 9 days	4 years 2 months 26 days	4 years 6 months 7 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance		$ 97,919
Number of Options, Granted	814,862	242,945
Weighted Average Exercise Price, Granted	$ 1.81	$ 3.43
Weighted Average Remaining Contractual Life, Granted	4 years 5 months 23 days	4 years 7 months 9 days
Aggregate Intrinsic Value, Granted
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited or cancelled	27,699
Weighted Average Exercise Price, Forfeited or cancelled	2 years 10 months 28 days
Aggregate Intrinsic Value, Forfeited or cancelled
Number of Options, Outstanding, Outstanding Balance	1,157,787	370,624	127,679
Weighted Average Exercise Price, Outstanding Ending Balance	$ 2.21	$ 3.15	$ 2.61
Aggregate Intrinsic Value, Outstanding, Ending Balance			$ 97,919
Number of Options, Expected to Vest in the Future Ending Balance	876,319	309,065
Weighted Average Exercise Price, Expected to Vest	$ 2.03	$ 3.23
Weighted Average Remaining Contractual Life, Expected to Vest	4 years 3 months	4 years 3 months 29 days
Aggregate Intrinsic Value, Outstanding, Expected of Vest
Number of Options, Exercisable	281,468	61,559
Weighted Average Exercise Price, Exercisable	$ 2.76	$ 2.78
Weighted Average Remaining Contractual Life, Exercisable	3 years 8 months 4 days	3 years 9 months
Aggregate Intrinsic Value, Outstanding, Exercisable
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	1,157,787	370,624
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 2.21	$ 3.15
Weighted Average Remaining Contractual Life, Vested, Exercisable and Options Expected to Vest	4 years 1 month 9 days	4 years 2 months 26 days
Aggregate Intrinsic Value, Outstanding,Exercisable and Options Expected to Vest
Number of Options, Forfeited or cancelled	(27,699)

Schedule of Warranty Activity (

Schedule of Warranty Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Warrants Outstanding, Beginning Balance	3,987,931	1,881,429
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 6.10	$ 7.57
Weighted Average Remaining Contractual Life Years,Ending Balance	1 year 2 months 8 days	2 years 1 month 6 days	4 years 1 month 28 days
Warrants, Granted		2,602,143
Weighted Average Exercise Price Outstanding, Granted		$ 4.36
Weighted Average Remaining Contractual Life Years, Granted		1 year 7 months 17 days
Warrants,Exercised		(495,641)
Weighted Average Exercise Price Outstanding,Exercised
Warrants, Forfeited or cancelled	164,652
Weighted Average Exercise Price Outstanding, Forfeited or cancelled
Warrants, Forfeited or cancelled	(164,652)
Warrants Outstanding, Ending Balance	3,823,279	3,987,931	1,881,429
Weighted Average Exercise Price Outstanding,Ending Balance	$ 4.66	$ 6.10	$ 7.57

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)

1 Months Ended

12 Months Ended

Dec. 31, 2022 USD ($) $ / shares shares

Aug. 09, 2022 shares

Jul. 01, 2022 $ / shares shares

Feb. 16, 2022 $ / shares shares

Jan. 03, 2022 $ / shares shares

Aug. 11, 2021 $ / shares shares

Jul. 29, 2021 shares

Mar. 31, 2021 USD ($) $ / shares shares

Mar. 26, 2021 shares

Feb. 28, 2021 shares

Jan. 31, 2021 USD ($) $ / shares shares

Nov. 19, 2020 shares

Mar. 31, 2022 shares

Sep. 30, 2021 shares

Jan. 31, 2020 $ / shares shares

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2020 shares

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

1,711,783

Share price per share | $ / shares

$ 3

Proceeds from public offering | $

$ 4,532,445

Term of warrants

2 years

5 years

Warrants exercise price | $ / shares

$ 3.75

Number of shares, warrants exercised

495,641

Warrants to purchase shares of common stock

2,190,000

Warrants exercisable date

May 24, 2021

Unrecognized share based compensation cost | $

$ 19,255

Preferred stock, shares authorized

10,000,000

10,000,000

10,000,000

Preferred stock, par value | $ / shares

$ 0.001

$ 0.001

$ 0.001

Preferred stock, shares issued

465

465

465

Preferred stock, shares outstanding

465

465

465

Number of shares granted, description

the Company granted a total of 487,473 options to 14 employees, 5 directors, and 2 consultants with vesting periods ranging from immediately upon issue to three years beginning March 16, 2022

the Company granted a total of 698,831 options to 35 employees, 4 directors, and 4 consultants with vesting periods ranging from immediately upon issue to three years beginning January 4, 2021

Number of shares granted

487,473

698,831

Vesting period

3 years

3 years

Share based compensation arrangement by award options vested

406,879

598,789

Allocation share based compensation expense | $

$ 907,373

$ 1,741,366

Share based compensation arrangement by award options vested outstanding

1,799,053

1,799,053

1,395,882

713,010

Stock issued during Stock options exercised

1,294,021

1,294,021

941,934

Share based compensation arrangement by award options grants

0

5,204

Allocation share based compensation expense | $

$ 793,251

$ 1,066,455

Allocation share based compensation expense | $

1,066,455

Options exercise price | $ / shares

$ 0.40

Stock options compensation cost | $

$ 741,728

$ 741,728

Weighted average remaining recognition period

1 year 9 months 21 days

Consultant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

10,000

13,500

3,000

Equity Option [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Allocation share based compensation expense | $

$ 1,047,200

Equity Option [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation arrangement by award options vested outstanding

1,799,053

1,799,053

1,395,882

2013 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

2,265,000

Common shares granted for the period

5,204

Common stock capital shares reserved for future issuance

500,000

2013 Stock Option Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock capital shares reserved for future issuance

436,506

436,506

Two Thousand Thirteen Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation arrangement by award options vested outstanding

1,749,053

1,749,053

1,345,882

2020 Stock Appreciation Rights Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

12,033

Unrecognized share based compensation cost | $

$ 982,519

$ 982,519

Options exercise price | $ / shares

$ 2.50

$ 2.50

$ 1.87

$ 3.42

$ 0.40

Weighted average remaining recognition period

2 years 1 month 20 days

2020 Stock Appreciation Rights Plan [Member] | President And Chief Executive Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

194,940

30,000

77,748

2020 Stock Appreciation Rights Plan [Member] | Vice President [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

25,117

30,313

2020 Stock Appreciation Rights Plan [Member] | Chief Technology Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

16,944

76,304

2020 Stock Appreciation Rights Plan [Member] | Chief Financial Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

69,470

48,580

CorProminence [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

1,500

Share price per share | $ / shares

$ 4.99

April 2020 Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

21,591

Number of shares, warrants exercised

191,204

Placement Agent Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price | $ / shares

$ 5.55625

Warrants to purchase shares of common stock

175,200

Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Percentage of warrant exercise price

1.25

Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Options exercise price | $ / shares

$ 1.30

Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member] | President And Chief Executive Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

181,947

Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member] | Vice President [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

87,335

Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member] | Chief Technology Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

97,038

Employee Retention Agreements [Member] | 2020 Stock Appreciation Rights Plan [Member] | Chief Financial Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares granted for the period

97,038

Series D Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

87,267

Preferred stock, shares outstanding

132

132

Series D Preferred Stock [Member] | Institutional Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Preferred stock, par value | $ / shares

$ 1,000

Share issued and sold during period, shares

1,640

Dividends percentage

9%

Conversion price per share | $ / shares

$ 2.50

Conversion description

In addition, a holder may at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price, which equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion. Upon the occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment defaults, breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set forth therein, the Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium to the underlying value of the Series D Preferred Shares being redeemed

Series E Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

61,651

Series E Convertible Preferred Stock [Member] | Other Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Conversion of stock, shares converted

48,544

Share issued and sold during period, shares

333

Dividends percentage

9%

Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

119,000

263,200

Private Placement [Member] | Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Term of warrants

2 years

Warrants exercise price | $ / shares

$ 4.32

Warrants to purchase shares of common stock

2,190,000

Public Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

2,190,000

Share price per share | $ / shares

$ 4.445

Proceeds from public offering | $

$ 8,736,488

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

136,943

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

3,823,279

3,823,279

Warrant description

expire between May 24, 2023 and January 8, 2026

Warrant [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price | $ / shares

$ 2.50

$ 2.50

Warrant [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price | $ / shares

$ 17.50

$ 17.50

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock issued during period

3,901,783

Common Stock [Member] | Placement Agent Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Percentage of warrant exercise price

0.08

Common Stock [Member] | Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Percentage of warrant exercise price

0.080

Common Stock [Member] | Series D Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Conversion of stock, shares converted

250

Number of shares as in-kind payment, shares

19,000

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
NOL carryover	$ 8,636,900	$ 6,729,300
Depreciation	(61,000)	41,700
Valuation allowance	(8,575,900)	(6,771,000)
Net deferred tax asset

Schedule of Reconciliation of t

Schedule of Reconciliation of the Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Book Loss	$ (1,837,400)	$ (1,572,500)
Depreciation	(20,700)	(25,700)
Meals & Entertainment		500
Stock Compensation	(48,548)	340,521
Change in valuation allowance	1,906,648	1,257,179
Provision for Income Taxes

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 41,128,000		$ 9,820,000
Operating loss carryforwards remainder	31,308,000
Deferred Tax Assets, Valuation Allowance	$ 8,575,900	$ 6,771,000
Federal statutory tax rate	21%	21%

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Loss from continuing Operations available to common stockholders (numerator)	$ (8,749,304)	$ (7,488,172)
Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)	10,498,802	9,828,541

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	1,294,021	941,934
Common Stock, Shares, Outstanding	10,498,802	10,498,802
Series D Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of Stock, Shares Issued	61,651	61,651
Equity Option [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	1,799,053	1,395,882
Common Stock, Shares, Outstanding	5,771,250	5,532,731
Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Class of Warrant or Right, Outstanding	3,823,279	3,987,931
Preferred Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Class of Warrant or Right, Outstanding	132	132
Warrant [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	87,267	87,267
Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of Stock, Shares Issued	333	333

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Expense form operating leases	$ 108,099	$ 101,004
Future minimum lease payments	$ 7,233

Schedule of Concentration of Ri

Schedule of Concentration of Risks (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue Benchmark [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	12.85%
Revenue Benchmark [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	12.20%
Revenue Benchmark [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration of risk percentage		27.81%
Revenue Benchmark [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration of risk percentage		17.23%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	31.11%	51.25%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	24.49%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	22.58%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration of risk percentage		46.34%

Concentrations (Details Narrati

Concentrations (Details Narrative) - Customer Concentration Risk [Member] - Customer [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	10%	10%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration of risk percentage	10%	10%

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Contribution plan description	The Company makes a Safe Harbor contribution match of 100% of each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed
Cost of contribution	$ 99,341	$ 86,554

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares		1 Months Ended
	Jan. 18, 2023	Jan. 26, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 26, 2021	Jan. 31, 2021
Subsequent Event [Line Items]
Preferred Stock, Shares Outstanding			465	465
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,190,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 3.75
Shares issued, price per share						$ 3
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		225,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.58
Conversion of stock, shares issued	3,083	270,828
Preferred Stock, Convertible, Conversion Price		$ 0.58
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1,648,302
Subsequent Event [Member] | January 2020 Warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		516,400
Subsequent Event [Member] | April 2020 Warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		383,306
Subsequent Event [Member] | January and April 2020 Warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.50
Series D Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Shares Outstanding			132
Series D Convertible Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Preferred Stock, Shares Outstanding		132
Series E Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of stock, shares issued	16.67
Shares issued, price per share	$ 10.30